Cost and convenience concerns around one of the most powerful osteoporosis treatments may soon become less prohibitive. The expensive monthly injections required for romosozumab—which uniquely both builds new bone while preventing breakdown—could potentially be shortened without sacrificing therapeutic benefit for postmenopausal women at high fracture risk.
The LIDA trial directly compared standard 12-month romosozumab treatment against a truncated 3-month course followed by denosumab maintenance therapy in 50 high-risk postmenopausal women. Both groups achieved statistically equivalent improvements in total hip bone mineral density, the study's primary endpoint. The abbreviated regimen met the predetermined non-inferiority threshold of staying within 2% of the full-duration treatment's effectiveness.
This finding addresses a critical clinical dilemma in osteoporosis management. Romosozumab produces superior bone density gains compared to other agents through its dual mechanism targeting the Wnt signaling pathway, but its bone-building effects naturally diminish after several months of use. The monthly clinic visits, substantial cost burden, and cardiovascular safety considerations have limited widespread adoption despite its efficacy advantages. A shorter treatment duration could preserve therapeutic benefits while reducing financial barriers and patient inconvenience.
The study's modest sample size and single-center design warrant cautious interpretation, however. Fracture prevention—the ultimate clinical goal—requires larger, longer-term studies to establish definitively. Additionally, the optimal transition strategy to maintenance therapy remains an evolving area of research. While these preliminary results suggest promise for more practical dosing regimens, broader validation will be essential before reshaping current osteoporosis treatment protocols.